Gh Release Research Peptides

13 research peptides demonstrate gh release properties. This collection covers their mechanisms, evidence base, and research applications.

Ipamorelin stands out as one of the most selective growth hormone secretagogues (GHS) available today. As a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5), it is designed to stimulate pulsatile GH release from the pituitary gland while exerting minimal influence on cortisol, prolactin, or appetite. Research indicates that Ipamorelin binds selectively to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, leading to an increase in cAMP levels and subsequent activation of protein kinase A, promoting GH secretion. Its unique structure allows it to target only the GH-releasing sites of the ghrelin receptor, which accounts for its lack of appetite stimulation and cortisol elevation, commonly observed with other peptides like GHRP-6. With a half-life of approximately 2 hours, Ipamorelin may require multiple daily doses, yet it does not appear to induce receptor desensitization, allowing for prolonged use without diminished efficacy.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that was initially developed for the treatment of HIV-associated lipodystrophy. This peptide exists in two forms: one with a Drug Affinity Complex (DAC) that extends its half-life to 5.8-8.1 days, and another, Mod GRF 1-29, which has a shorter half-life of approximately 30 minutes. Clinical trials conducted in 2006 demonstrated significant dose-dependent increases in GH and IGF-1 levels in healthy adults, with increases ranging from 2-10 fold for GH and 1.5-3 fold for IGF-1. CJC-1295 functions by binding to GHRH receptors on pituitary somatotroph cells, activating cAMP signaling pathways that stimulate both GH gene transcription and pulsatile GH release. The DAC version, while effective, may lead to non-physiological GH elevations and potential receptor desensitization, while Mod GRF 1-29 mimics natural GH release patterns, reducing risks associated with constant hormone elevation.

Sermorelin is a synthetic peptide composed of 29 amino acids, corresponding to the first segment of natural growth hormone-releasing hormone (GHRH). This peptide plays a crucial role in preserving the body's natural GH feedback loop through somatostatin, making it a safer alternative to exogenous human growth hormone (HGH). Notably, the 1997 JCEM trial provided robust evidence of Sermorelin's efficacy, showing significant improvements in IGF-1 levels, body composition, and overall well-being over a 5-month period. Mechanistically, Sermorelin binds to GHRH receptors in the anterior pituitary, stimulating both the transcription of the HGH gene and the pulsatile release of endogenous GH. This approach helps maintain the physiological feedback loop, reducing risks such as insulin resistance associated with continuous high levels of HGH. With a half-life of approximately 11-12 minutes, the effects of Sermorelin can persist for weeks to months, activating regenerative processes and mitigating the risk of tachyphylaxis compared to direct HGH injections.

Tesamorelin is a growth hormone secretagogue that has received FDA approval for its role in stimulating endogenous GH and IGF-1 production. Phase 3 clinical trials have demonstrated its efficacy in reducing visceral fat, showcasing a favorable safety profile over a treatment duration of 26 weeks. The mechanism of action involves binding to human growth hormone-releasing factor (GRF) receptors on the anterior pituitary, mimicking endogenous GRF and promoting GH synthesis and release. This leads to elevated levels of IGF-1 and insulin-like growth factor binding protein 3 (IGFBP-3), facilitating lipolysis and the subsequent reduction of visceral adipose tissue. Additionally, GH's influence on cytochrome P450 enzymes may have implications for the metabolism of co-administered medications, warranting further investigation into potential drug interactions.

GHRP-6, a synthetic hexapeptide, is recognized for its potent capabilities as a growth hormone secretagogue. By binding to the ghrelin receptor (GHS-R1a), it stimulates pulsatile GH release from the pituitary gland while maintaining essential physiological feedback mechanisms. As one of the earliest developed GH-releasing peptides, GHRP-6 is notable for its significant appetite-stimulating effects, which arise from its action on the ghrelin receptor. Preclinical studies have also highlighted its cytoprotective properties via interactions with the CD36 receptor, suggesting potential cardioprotective, neuroprotective, and anti-fibrotic effects. The peptide's mechanism involves mimicking ghrelin, triggering GH release and increasing IGF-1 levels while ensuring that endogenous somatostatin levels rise in response to prevent excessive GH elevation. With a half-life of approximately 2.5 hours, GHRP-6 is effective in modulating GH levels while also inducing mild, transient increases in cortisol and ACTH, which are generally considered not clinically significant.

GHRP-2 (pralmorelin) is a synthetic hexapeptide classified as a growth hormone secretagogue (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol). It is recognized for its potent, dose-dependent stimulation of GH release via the ghrelin receptor (GHS-R). Research indicates that GHRP-2 is more potent than GHRP-6 while eliciting less appetite stimulation. Approved in Japan as a diagnostic agent for GH deficiency, it has demonstrated sustained efficacy in promoting growth velocity in GH-deficient children over 8-24 months. Clinical studies reveal a safety profile comparable to placebo at therapeutic doses, supporting its use in diagnostic settings. Notably, a GH response cutoff of 15 mcg/L is utilized to distinguish between GH deficiency and healthy controls.

MK-677 (Ibutamoren) stands out as a potent, long-acting, orally active non-peptide agonist of the ghrelin receptor (GHS-R1a), facilitating growth hormone release without the need for injections. Unlike injectable GH peptides, MK-677 has been shown to maintain elevated levels of GH and IGF-1 for up to 24 hours post-administration. Mechanistically, MK-677 mimics the action of ghrelin, activating GH secretagogue pathways in the pituitary gland and hypothalamus, which enhances the natural pulsatile release of growth hormone. Studies suggest that it does not suppress the hypothalamic-pituitary axis nor significantly affect cortisol levels at therapeutic doses, making it a unique option for sustained GH elevation.

Hexarelin, a synthetic hexapeptide, is noted for its robust action as a growth hormone secretagogue due to its binding affinity for the ghrelin receptor (GHS-R1a). Research indicates that Hexarelin can elicit greater GH release compared to GHRH alone; however, it is characterized by a relatively rapid receptor desensitization, which limits its cycle duration to 4-8 weeks. In addition to its potent GH-releasing effects, Hexarelin exhibits cardioprotective properties independent of GH release, attributed to its interaction with CD36 scavenger receptors on cardiac tissue. This multifaceted mechanism includes direct stimulation of pituitary somatotrophs, activation of hypothalamic GHRH neurons, and suppression of somatostatin, thereby enhancing GH pulses.

Alexamorelin is a synthetic growth hormone-releasing peptide (GHRP) that shares structural similarities with GHRP-6. Despite its potential as a GH secretagogue, it has been subjected to limited preclinical studies and has not progressed to significant clinical development. The existing literature on Alexamorelin is sparse, rendering it an obscure compound in the realm of GH research. It is hypothesized to function as a ghrelin receptor (GHS-R1a) agonist, stimulating GH release from the anterior pituitary, yet detailed pharmacological characterization remains underexplored.

Tabimorelin (NN703) is an orally active synthetic growth hormone secretagogue developed by Novo Nordisk. It has undergone Phase II clinical trials, demonstrating significant GH release in both healthy individuals and those with GH deficiency. However, despite its promising pharmacological profile, development was halted, likely due to an unfavorable efficacy-to-side-effect ratio for chronic use. Tabimorelin is one of the better-characterized oral GH secretagogues, acting as a ghrelin receptor (GHS-R1a) agonist, with studies indicating that single oral doses can produce dose-dependent GH release peaking within 30-60 minutes. Additionally, it has been shown to modestly increase cortisol, prolactin, and ACTH levels.

Macimorelin (Macrilen) is an orally active growth hormone secretagogue that received FDA approval in December 2017 as a diagnostic tool for adult growth hormone deficiency (AGHD). Its mechanism involves stimulating GH release, with the peak response measured to assess GH deficiency. Clinical trials have shown that Macimorelin has a 92% concordance with the insulin tolerance test (ITT), which has traditionally been the gold standard for diagnosing GH deficiency. The advantages of Macimorelin include its non-invasive oral administration and the absence of the need to induce hypoglycemia, enhancing its safety and practicality. Following oral administration, GH levels peak approximately 30-90 minutes later, with a confirmed deficiency indicated by a blood GH level below 2.8 ng/mL at specified intervals.

HGH Fragment 176-191 is a synthetic peptide that corresponds to the C-terminal region (amino acids 176-191) of human growth hormone. This 16-amino acid fragment has been identified as critical for GH's lipolytic activity, which plays a role in fat metabolism. Although a stabilized analog, AOD-9604, progressed to Phase III clinical trials, it ultimately did not demonstrate sufficient efficacy for obesity treatment and was not approved for clinical use. Additionally, the World Anti-Doping Agency (WADA) prohibits this peptide due to its performance-enhancing potential.

Mechanism: Research indicates that HGH Fragment 176-191 mimics the lipolytic effects of the C-terminal loop of growth hormone, promoting fat breakdown while inhibiting fat formation within adipose tissue. Studies conducted by Ng and Borstein at the University of Melbourne revealed that this fragment effectively stimulated lipolysis in ob/ob mouse adipose tissue at concentrations comparable to full-length GH. Importantly, it does not compete with GH for receptor binding and does not induce GH-like effects on blood glucose levels or insulin sensitivity, suggesting a unique action pathway that may be leveraged for specific metabolic interventions.

Anamorelin is a synthetic peptide designed as an orally active agonist of the ghrelin receptor (GHS-R1a), primarily developed for addressing cancer-related cachexia. In contrast to endogenous ghrelin, which has a very short half-life, anamorelin is formulated for once-daily oral administration, providing sustained activation of the receptor. In 2021, it received regulatory approval in Japan for use in patients suffering from cachexia associated with non-small cell lung cancer (NSCLC), gastric, pancreatic, and colorectal cancers. This makes anamorelin one of the few peptide-derived therapeutics explicitly indicated for cachexia. However, it has not yet received approval from the FDA or EMA, underscoring the need for further validation in broader markets.

Mechanism: Anamorelin selectively activates GHS-R1a, a G protein-coupled receptor that plays a crucial role in appetite regulation. Activation of GHS-R1a within the hypothalamus stimulates orexigenic neurons in the arcuate nucleus, thereby enhancing neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling while simultaneously suppressing anorexigenic pro-opiomelanocortin (POMC) pathways. This dual action results in a sustained increase in appetite. Furthermore, in the anterior pituitary, GHS-R1a activation promotes growth hormone release from somatotrophs through mechanisms that are synergistic but distinct from those activated by hypothalamic growth hormone-releasing hormone (GHRH). The resultant increase in GH levels subsequently drives insulin-like growth factor 1 (IGF-1) production, supporting anabolic processes such as protein synthesis and maintenance of lean body mass.